AML represents a disease that develops from the uncontrolled growth and survival of undifferentiated leukemia stem cells. These stem cells are particularly dependent for survival upon the MCL-1 ...

and cell death. Abnormalities in tyrosine kinases are common in AML, and constitute an attractive therapeutic target. An example is given by the balanced chromosomal translocations (TEL-Abl ...

The chromosomes of these leukemia cells are in a state of enormous ... One subclone, which only accounted for about five percent of the original AML, proved to be very dominant in the transplanted ...

AML represents a disease that develops from the uncontrolled growth and survival of undifferentiated leukemia stem cells. These stem cells are particularly dependent for survival upon the MCL-1 ...

Acute myeloid leukemia (AML) is one of the most aggressive and genetically complex cancers, marked by the unchecked growth of immature myeloid cells. Its diversity stems from numerous genetic ...

Patients with acute myeloid leukemia who relapse after stem cell transplantation have just a small chance of survival: doctors can give them additional donor T cells to fight the cancer, but only ...

The AACR poster presentation will provide an update on the data in AML patients most recently presented at the American Society of Hematology (ASH) Annual Meeting 2024 showing that ICT01 administered ...

Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...

pharmacodynamics and dose selection data on the novel γ9δ2 T-cell activator, ICT01, in combination with azacitidine and venetoclax for the treatment of patients with newly diagnosed AML.